My purpose for attending the ASH conference was two-fold; first, to develop a clearer understanding of what the options can be for the next phase of treatment for my disease, which I will also be able to share with the patients my wife and I coach. Second, to meet fellow myeloma patients and Myeloma Coaches who share this experience with my wife and I.
I have always understood that to date there is no “silver bullet” to cure multiple myeloma. However, after listening to a few of the presentations I realized how quickly one can move from the optimistic mindset that my oncology team has helped me to develop, to the stark reality of “oh my gosh, is this what is going to happen to me?”
The most encouraging data shared was clearly the number of either FDA approved, FDA pending, or in-trial drugs currently available (close to 20, a remarkable and impressive statistic) which was reassuring for a patient like me who is in the third phase of treatment. I am reminded of the struggles my older brother had while on Pomalyst, the last drug available to him before he succumbed to this very same disease. He passed away in 2016 and since that time so many new drugs and treatment protocols have been approved, with very positive results.
So there are three important take-aways for me from this conference.
Thank you to our Myeloma Coach ASH 2019 sponsors:
about the author
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.